Heartflow

HeartFlow is a digital health company focused on advanced, non-invasive cardiac diagnostic technology for coronary artery disease (CAD). Founded in Palo Alto, the company originated from research at Stanford University. HeartFlow utilizes artificial intelligence, computational fluid dynamics, and 3D modeling to enhance the detection and management of CAD. The flagship product, HeartFlow FFRct Analysis, is the first FDA-cleared non-invasive technology that quantifies the impact of CAD on blood flow using standard coronary CT angiography images. This technology creates a personalized 3D model of a patient's heart, allowing physicians to visualize arterial blockages and assess their severity without invasive procedures. HeartFlow also offers additional FDA-cleared tools, including Plaque Analysis and Roadmap™ Analysis, which provide detailed insights into coronary plaque and arterial narrowings. HeartFlow's services are available globally through partnerships with over 1,000 hospitals, ensuring rapid turnaround times and high acceptance rates for CCTA scans. The company's technology supports cardiologists, radiologists, and interventionalists in improving diagnostic accuracy and personalizing treatment plans, ultimately enhancing patient care and reducing the burden of heart disease.

• Employees 630
• Founded 2010
• Annual Revenue $138526000
• Total Funding $1538528811